“塞来昔布”、“氟康唑”、“酮康唑”、“舍曲林”、“噻氯匹定”、“曲格列酮”-"celecoxib","fluconazole","ketoconazole","sertraline","ticlopidine","troglitazone"
变量_单倍型
CYP2C19*1, CYP2C19*15
药物名称(英)
"celecoxib","fluconazole","ketoconazole","sertraline","ticlopidine","troglitazone"
药物名称(中)
“塞来昔布”、“氟康唑”、“酮康唑”、“舍曲林”、“噻氯匹定”、“曲格列酮”
记事
The fluorogenic substrate 3-cyano-7-ethoxycoumarin (CEC) was incubated with CYP2C19 microsomal protein harboring human CYP2C19 variants to assay enzyme activity, standardized to protein concentration. "Sensitivity" refers to the extent of inhibition relative to CYP2C19*1A (WT) and quantified by IC50. The inhibitory effect of the following drugs was tested for each CYP2C19 variant: celecoxib, troglitazone, fluconazole, ketoconzale, omeprazole, ticlopidine, fluoxetine, sertraline, fluvoxamine, tranylcypromine.
专家论述
CYP2C19 *15 is not associated with sensitivity to celecoxib, fluconazole, ketoconazole, sertraline, ticlopidine and troglitazone as compared to CYP2C19 *1.